AcelRx Pharmaceuticals

company

About

AcelRx Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of pain and other conditions.

  • 51 - 100

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$40M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2005
Number Of Employee
51 - 100
Operating Status
Active

AcelRx Pharmaceuticals is a specialty pharmaceutical company, that engages in the development and commercialization of therapies for the treatment of pain and other conditions. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate for the management of acute postoperative pain in the hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures. It serves patients, physicians, regulators, and payers.

AcelRx Pharmaceuticals was founded in 2005 and is based in Redwood City, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$40M
AcelRx Pharmaceuticals has raised a total of $40M in funding over 2 rounds. Their latest funding was raised on Dec 19, 2013 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 19, 2013 Post-IPO Debt $40M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
AcelRx Pharmaceuticals is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Post-IPO Debt